liposomal amphotericin B

Indicated for treatment of Aspergillus species, Candida species, and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or if renal impairment or unacceptable toxicity precludes use of amphotericin B deoxycholate

Liposomal formulations have been found to have less renal toxicity than deoxycholate,and fewer infusion-related reactions. They are more expensive than amphotericin B deoxycholate.

  • aspergillosis
    • First-line treatment of invasive aspergillosis is with a triazole (voriconazole, posaconazole, or isavuconazole); amphotericin B deoxycholate or liposomal amphotericin B can be used for amphotericin-sensitive Aspergillus species if triazoles a re not available. When possible, reversal of immunosuppression improves treatment response.